Table 2.
Prevalence of HR-HPV infection in SNSCC by detection method and genotype
| Authors and year | SNSCC cases | HPV + cases | HPV + % | Detection methods |
HPV genotypes |
||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| p 16 IHC | HPV DNA ISH | HPV DNA PCR | HPV E6/E7 mRNA ISH | HPV E6/E7 mRNA PCR | HPV 16 | HPV 18 | HPV others | ||||
| Laco et al. 2015 [49] | 49 | 17 | 34% | 16/49 (33%) | 12/49 (24%) | 8/42 (19%) | 13/49 (26%) | 8/46 (17%) | 4/17 (23%) | 5/17 (29%) | HPV-35 1/17 (5%); 7/17—Unknown |
| Yamashita et al. 2015[47] | 16 | 4 | 25% | 1/4 (25%) | NA | 4/16 (25%) | NA | NA | 3/4 (75%) | 1/4 (25%) | NA |
| Chung et al. 2015 [51] | 26 | 14 | 53% | NA | NA | 14/26 (53%) | NA | NA | NA | NA | NA |
| Doescher et al. 2015 [33] | 44 | 3 | (3/42) 7% | 13/44 (29.5%) | 9/44 (20.5%) | NA | NA | NA | NA | NA | NA |
| Becker 2016 [52] | 39 | 4 | 10.8% | NA | NA | 4/39 (10.8%) | NA | NA | 3/4 (75%) | NA | NA |
| Chowdhury 2017 [45] | 26 | 16 | 62% | 17/19 (89%) | NA | 16/26 (62%) | NA | NA | 8/16 (50%) | 2/16 (12.5%) | HPV-33 1/16 (6.25%); HPV-35 1/16 (6.25%); HPV-39 1/16 (6.25%); HPV-42 1/16 (6.25%); HPV-82 1/16 (6.25%) |
| Sahnane et al. 2018 [53] | 12 | 1 | 8% | 12/12 (100%) | 1/12 (8%) | NA | NA | NA | NA | NA | NA |
| Ambreen et al. 2018 [50] | 10 | 2 | 20% | NA | NA | 2/10 (20%) | NA | NA | 2/2 (100%) | 1/2 (50%) | NA |
| Udager et al. 2018 [54•] | 14 | 5 | 35.7% | NA | NA | 5/14 (35.7%) | NA | NA | 2/5 (40%) | 1/5 (20%) | HPV-33 1/5 (20%); 1/5—Unknown |
| Bulane et al. 2019 [55] | 25 | 4 | 16% | NA | NA | 4/25 (16%) | NA | 4/4 (100%) | 1/4 (25%) | 1/4 (25%) | HPV-45 2/4 (50%) |